EIF2AK2 and pulmonary venoocclusive disease: Consequently, targeted therapy with the PKR inhibitor C16 or the ISR inhibitor ISRIB substantially mitigates the condition, while preventive treatment with ISRIB entirely reverses the progression of PVOD [145].